NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: GeoVax's Broad-Spectrum COVID-19 Vaccine Patent Allowance
TL;DR
GeoVax's new patent provides a competitive edge with a multi-antigen vaccine platform offering broader, longer-lasting protection against evolving viruses compared to single-antigen mRNA vaccines.
GeoVax's patented vaccine uses a Modified Vaccinia Ankara platform to deliver three SARS-CoV-2 proteins, creating a broader immune response through multiple antigen stimulation.
GeoVax's multi-antigen vaccine technology aims to better protect vulnerable immunocompromised populations and enhance global pandemic preparedness for a safer future.
GeoVax's innovative vaccine includes three viral proteins instead of just one, potentially creating more durable immunity as the virus continues to mutate.
Found this article helpful?
Share it with your network and spread the knowledge!
GeoVax Labs announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for their patent application covering a novel COVID-19 vaccine design that delivers three key structural proteins of the SARS-CoV-2 virus.
Unlike current mRNA vaccines that rely solely on the Spike protein, GeoVax's design uses its proprietary Modified Vaccinia Ankara (MVA) platform to deliver three key structural proteins: Spike (S), Membrane (M), and Envelope (E) of SARS-CoV-2.
This patent strengthens GeoVax's intellectual property portfolio for its multi-antigen vaccine platform, validates their innovative approach to vaccine design, and supports their goal of providing broader, longer-lasting protection, especially for vulnerable populations.
By including multiple antigens, the vaccine is designed to trigger a broader and more durable immune response that could maintain protection even as the virus continues to evolve.
GEO-CM04S1 is GeoVax's dual-antigen COVID-19 vaccine candidate designed to stimulate both antibody and T-cell immune responses, currently in Phase 2 clinical trials across several patient populations.
David A. Dodd is the Chairman and Chief Executive Officer of GeoVax who stated that this patent allowance validates their innovative approach to move beyond single antigen delivery technologies to provide broader, longer-lasting protection.
The same technology platform underpins GeoVax's programs for targeting smallpox and hemorrhagic fever viruses, supporting U.S. and global efforts to expand vaccine manufacturing and pandemic preparedness.
The vaccine is being evaluated as a primary vaccine for immunocompromised patients, a booster for patients with chronic lymphocytic leukemia (CLL), and a durable booster for healthy adults previously vaccinated with mRNA vaccines.
GeoVax develops novel vaccines against infectious diseases and therapies for solid tumor cancers, including a vaccine targeting Mpox and smallpox, and an oncolytic solid tumor gene-directed therapy called Gedeptin® for advanced head and neck cancers.
This announcement was made on December 16, 2025, as reported in a press release from GeoVax Labs, Inc.
Curated from NewMediaWire
